New pill may stop vomiting from weight-loss drugs
NCT ID NCT06804603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether tradipitant, an oral capsule, can reduce nausea and vomiting in healthy overweight or obese volunteers who also received a GLP-1 receptor agonist (a class of weight-loss drugs). 124 participants were randomly assigned to tradipitant or a placebo. The main goal was to see if fewer people in the tradipitant group had vomiting episodes each week, tracked using a daily symptom diary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tradipitant
What this could lead to
If it works, tradipitant could help people taking GLP-1 drugs for weight loss or diabetes by reducing the nausea and vomiting that often cause people to stop treatment.
What could go wrong
This is a small, early-phase study in healthy volunteers, not patients. The results may not apply to real-world use, and tradipitant might not prove effective or safe in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanda Investigational Site
Los Angeles, California, 90025, United States
-
Vanda Investigational Site
Rochester, Minnesota, 55905, United States
-
Vanda Investigational Site
New York, New York, 10016, United States